ArticleJournal of experimental pharmacology2019
Enhanced efficacy of chemically modified curcumin in experimental periodontitis: systemic implications.
Article in Journal of experimental pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Curcumin as an adjunct in periodontal therapy: local effects, delivery systems, and clinical perspectives.Frontiers in dental medicine · 2026Review
- A novel modified-curcumin 2.24 suppresses MMPs in a periodontal-relevant cell culture model: a pilot study.Frontiers in oral health · 2026Article
- Proteolytic dysfunction in bovine digital dermatitis caused by Treponema spp. and the therapeutic use of non-antimicrobial matrix metalloproteinase inhibitors.Communications biology · 2025Article
- Characterization and application of in situ curcumin/ZNP hydrogels for periodontitis treatment.BMC oral health · 2024Article
- Host modulation therapy in periodontitis, diagnosis and treatment-status update.Frontiers in dental medicine · 2024Article
- Review
- Effect ofFrontiers in microbiology · 2023Article
- Photodynamic Therapy with Natural Photosensitizers in the Management of Periodontal Disease Induced in Rats.Gels (Basel, Switzerland) · 2022Article
- Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies.BioMed research international · 2022Review
- The Maximum-Tolerated Dose and Pharmacokinetics of a Novel Chemically Modified Curcumin in Rats.Journal of experimental pharmacology · 2022Article
- Anti-Periodontitis Effect of Ethanol Extracts ofNutrients · 2021Article
- From Simple Mouth Cavities to Complex Oral Mucosal Disorders-Curcuminoids as a Promising Therapeutic Approach.ACS pharmacology & translational science · 2021Review
- A Novel Modified-Curcumin Promotes Resolvin-Like Activity and Reduces Bone Loss in Diabetes-Induced Experimental Periodontitis.Journal of inflammation research · 2021Article
- Does Chemically Modified Curcumin Control the Progression of Periodontitis? A Systematic Review.Journal of experimental pharmacology · 2021Review
- Chemically modified curcumin (CMC2.24) alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis.Journal of molecular medicine (Berlin, Germany) · 2020Article
- Sulfur-containing amino acids in aged garlic extract inhibit inflammation in human gingival epithelial cells by suppressing intercellular adhesion molecule-1 expression and IL-6 secretion.Biomedical reports · 2020Article
- The preventive and therapeutic application of garlic and other plant ingredients in the treatment of periodontal diseases.Experimental and therapeutic medicine · 2020Review
- Graph attention network predicts drug-gene associations of matrix metalloproteinases 9-based host modulation in periodontitis.Journal of Indian Society of PeriodontologyArticle
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
introductionDental microbial biofilm initiates gingival inflammation, and its suppression is the current dominant strategy for treating periodontitis. However, the host response to the biofilm is largely responsible for the connective tissue breakdown including alveolar bone loss, which is mediated by proinflammatory cytokines and matrix metalloproteinases (MMPs).
methodsThe current study compared the efficacy of a novel host-modulation compound, a chemically modified curcumin (CMC 2.24), to that of its parent compound (natural curcumin), in both lipopolysaccharide (LPS) (a bacterial endotoxin)-induced cell culture and in vivo models of periodontitis.
resultsIn cell culture, both CMC 2.24 and curcumin appeared similarly effective in suppressing LPS-induced cytokine (IL-1β and TNF-α) secretion by mononuclear inflammatory cells; however, CMC 2.24 significantly reduced MMP-9 secretion by 78% (
conclusionThese data, plus that from previous studies, support the therapeutic potential of CMC 2.24 in the management of inflammatory periodontal disease and its ability to reduce the risk of associated systemic diseases. The current study also indicates that the MMP-9 inhibitor efficacy is associated with the ability of CMC 2.24 (but not curcumin) to inhibit alveolar bone loss in this rat model of periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.